Thromboembolism – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Thromboembolism – Pipeline Review, H1 2020’, provides an overview of the Thromboembolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Thromboembolism

– The report reviews pipeline therapeutics for Thromboembolism by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Thromboembolism therapeutics and enlists all their major and minor projects

– The report assesses Thromboembolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Thromboembolism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Thromboembolism

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Accu-Break Pharmaceuticals Inc

Acticor Biotech SAS

Bayer AG

Bristol-Myers Squibb Co

China Biologic Products Holdings Inc

China Resources Emde Biological Pharmaceutical Co Ltd

CSPC Pharmaceutical Group Ltd

Daiichi Sankyo Co Ltd

Espero BioPharma Inc

EVAS Therapeutics LLC

F. Hoffmann-La Roche Ltd

GC Pharma

Indiana Lysis Technologies LLC

Ionis Pharmaceuticals Inc

Laboratorios Farmaceuticos Rovi SA

Les Laboratoires Servier SAS

Ono Pharmaceutical Co Ltd

Portola Pharmaceuticals Inc

Tasly Pharmaceutical Group Co Ltd

Tetherex Pharmaceuticals Corp

Tianjin Pharmaceuticals Group Co Ltd

Translational Sciences Inc

Valeo Pharma Inc

Verseon Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thromboembolism - Overview

Thromboembolism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thromboembolism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thromboembolism - Companies Involved in Therapeutics Development

Accu-Break Pharmaceuticals Inc

Bayer AG

Bristol-Myers Squibb Co

China Biologic Products Holdings Inc

CSPC Pharmaceutical Group Ltd

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

GC Pharma

Ionis Pharmaceuticals Inc

Laboratorios Farmaceuticos Rovi SA

Ono Pharmaceutical Co Ltd

Portola Pharmaceuticals Inc

Tasly Pharmaceutical Group Co Ltd

Tetherex Pharmaceuticals Corp

Verseon Corp

Thromboembolism - Drug Profiles

antithrombin III (human) - Drug Profile

betrixaban - Drug Profile

BMS-986177 - Drug Profile

Drugs for Pulmonary Embolism - Drug Profile

DS-1040 - Drug Profile

edoxaban tosylate - Drug Profile

enoxaparin sodium - Drug Profile

GC-2107 - Drug Profile

IONIS-FXIRx - Drug Profile

Lysimab - Drug Profile

ONO-7684 - Drug Profile

osocimab - Drug Profile

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile

Recombinant Protein for Thromboembolism - Drug Profile

rivaroxaban - Drug Profile

SelK-2 - Drug Profile

SYHA-136 - Drug Profile

TAP-ANV - Drug Profile

tecarfarin sodium - Drug Profile

TRX-1 - Drug Profile

urokinase - Drug Profile

VE-1902 - Drug Profile

VE-2851 - Drug Profile

warfarin potassium - Drug Profile

YG-001 - Drug Profile

Zifa-01 - Drug Profile

Thromboembolism - Dormant Projects

Thromboembolism - Discontinued Products

Thromboembolism - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Thromboembolism, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Thromboembolism – Pipeline by Accu-Break Pharmaceuticals Inc, H1 2020

Thromboembolism – Pipeline by Acticor Biotech SAS, H1 2020

Thromboembolism – Pipeline by Bayer AG, H1 2020

Thromboembolism – Pipeline by Bristol-Myers Squibb Co, H1 2020

Thromboembolism – Pipeline by China Biologic Products Holdings Inc, H1 2020

Thromboembolism – Dormant Projects, H1 2020

Thromboembolism – Dormant Projects, H1 2020 (Contd..1), H1 2020

Thromboembolism – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Thromboembolism, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports